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A nested case-control study was carried out using data from the US Department of Defense cohort between
2000 and 2013 to investigate the associations of papillary thyroid cancer (PTC) with serum concentrations of
polybrominated diphenyl ethers and polybrominated biphenyls. This study included 742 histologically confirmed
PTC cases (in 341 women and 401 men) and 742 matched controls with prediagnostic serum samples from the
Department of Defense Serum Repository. Lipid-corrected serum concentrations of 8 congeners were measured.
Multivariate conditional logistic regression analyses were performed for classical PTC and follicular variant of PTC,
respectively. We also examined effect modification by sex. BDE-28, a polybrominated diphenyl ether congener,
was associated with significantly increased risk of classical PTC (for the third tertile vs. below the limit of detection,
odds ratio = 2.09, 95% confidence interval: 1.05, 4.15; P for trend = 0.02), adjusting for other congeners, body
mass index, and branch of military service. This association was observed mainly for larger classical PTC (tumor
size >10 mm), with a significantly stronger association among women than men (P for interaction = 0.004). No
consistent associations were observed for other congeners, including those at higher concentrations. This study
found a significantly increased risk of classical PTC associated with increasing levels of BDE-28. The risk varied
by sex and tumor size.
papillary thyroid cancer; PBBs; PBDEs; polybrominated biphenyls; polybrominated diphenyl ethers
Abbreviations: BDE, brominated diphenyl ether; BMI, body mass index; CI, confidence interval; ICD-O-3, International
Classification of Diseases for Oncology, Third Revision; LOD, limit of detection; NHANES, National Health and Nutrition
Examination Survey; OR, odds ratio; PBB, polybrominated biphenyl; PBDE, polybrominated diphenyl ether; PTC, papillary
thyroid cancer.
Thyroid cancer is the most prevalent cancer of the
endocrine system, and its incidence has been increasing
faster than that of any other malignancy (1). In the United
States, the incidence of thyroid cancer increased by 148%
among men (from 3.1 to 7.7 per 100,000 persons) and by
247% among women (from 6.4 to 22.2 per 100,000 persons)
between 1975 and 2014 (2). A pattern of increasing rates was
also observed in US military personnel, among men (from
2.53 to 2.76 per 100,000 persons) and women (from 9.62 to
13.51 per 100,000 persons) between the periods 1990–1997
and 1998–2004, and the incidence was significantly higher
in military women than women in the general population
for ages 20–49 years (3). The majority of the increase
is for papillary thyroid cancer (PTC), the most common
histological type, accounting for more than 80% of all
thyroid carcinomas (4, 5). While the increased detection
of occult disease has contributed to the increasing trend, it
has also been suggested that environmental chemicals or
physical agents play a role (6–8).
Since the 1970s, polybrominated diphenyl ethers (PBDEs)
and polybrominated biphenyls (PBBs) have been widely
used as flame retardants among the US general and military
population in a variety of commercial and household
products, including plastics, furniture, upholstery, textiles,
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electrical equipment, and electronic devices (9, 10). Because
PBDEs and PBBs are physically mixed into products, they
have the potential to release into the environment and enter
the human body (9, 10). Environmental and human levels
of PBDEs have been increasing rapidly in the last three
decades (7). Due to concerns about increasing exposure and
potential associations with adverse health outcomes, the US
government banned the production of PBBs in 1976 and
increased regulations on PBDEs in 2004 (11, 12). Despite
this, PBDEs and PBBs remain ubiquitous in the environment
and are being detected in human populations due to their
persistence and bioaccumulation (7, 10). Among Michigan
women exposed to PBBs in an accidental contamination
of food supply (1973–1974), blood concentrations of PBB-
153 in 2004 were still substantially higher when compared
with National Health and Nutrition Examination Survey
(NHANES) data 2003–2004 (13, 14). Although some inves-
tigations on temporal trends of PBDE body burdens suggest
a moderate decline starting approximately after 2000 (12,
15), others have reported a significant increase of several
PBDE congeners from 2011–2015 (11, 16). The observed
trends suggest PBDEs could be following the trend of other
legacy pollutants, where temporal declines were followed
by an exposure plateau that persisted for decades (11, 15).
Experimental evidence has suggested that exposures to
PBDEs and PBBs are related to disruption of thyroid hor-
mone homeostasis and thyroid function in vitro and in rats
(17, 18), but epidemiologic studies have yielded conflicting
findings in the associations between PBDE and PBB expo-
sures and thyroid function (13, 19–21).
Animal studies of carcinogenicity of PBDEs are limited
to decabrominated diphenyl ethers (BDEs). These studies
report a slightly elevated incidence of thyroid gland ade-
noma or carcinoma (combined) and a significantly increased
incidence of follicular cell hyperplasia, which is considered
to be a precursor of thyroid tumors, in exposed mice (9). To
our knowledge, only two epidemiologic studies have inves-
tigated the relationship between exposure to PBDEs and risk
of thyroid cancer. One study, including 70 PTC cases and 70
controls, reported a positive association with BDE-209 (22),
while another, including 104 cases and 207 controls, did not
find any associations (23). To our knowledge, no previous
studies have evaluated PBB exposures in relation to risk of
thyroid cancer.
Considering parallel increasing trends of thyroid can-
cer incidence and PBDE body burdens, combined with the
paucity of epidemiologic studies directly investigating their
association, we conducted a nested case-control study using
data from the Department of Defense Automated Central
Tumor Registry and the Defense Medical Surveillance Sys-
tem, with prediagnostic serum samples from the Department
of Defense Serum Repository, to investigate the associations
of PTC with serum concentrations of PBDEs and PBBs.
METHODS
Study population
Detailed information regarding the study design has been
published elsewhere (24). In brief, 742 pairs of PTC cases
and controls were selected from US military personnel who
had serum samples stored in the Department of Defense
Serum Repository. Serum samples from all military mem-
bers were drawn during active duty. Inclusion criteria for
cases: 1) histologically confirmed (International Classifica-
tion of Diseases for Oncology, Third Revision (ICD-O-3):
8050, 8260, and 8340–8343); 2) at least 3 0.5-mL predi-
agnostic (total 1.5 mL) and 1 0.5-mL postdiagnostic serum
samples stored in the Department of Defense Serum Repos-
itory since 1989; 3) diagnosis between 2000 and 2013; 4)
age 21 years or older at diagnosis; and 5) without any
cancers (except for nonmelanoma skin cancer) prior to the
date of PTC diagnosis. Controls who had no diagnosis with
any cancer (except for nonmelanoma skin cancer) were
randomly selected and individually matched to cases on date
of birth (within 1 year), sex, race/ethnicity, and midpoint
of dates of the selected 4 samples drawn (within 1 year).
Demographic and military characteristics for all participants
were abstracted from the DefenseMedical Surveillance Sys-
tem. All study procedures were approved by the Uniformed
Services University Institutional Review Board, the Walter
Reed National Military Medical Center, the Department of
Defense Joint Pathology Center, and the Human Investiga-
tion Committee of Yale University. The involvement of the
Centers for Disease Control and Prevention laboratory did
not constitute engagement in human subjects research.
Measurement of PBDEs and PBBs
Serum concentrations of PBDEs and PBBs were mea-
sured in the earliest prediagnostic serum sample. The mea-
surement was conducted at the Persistent Organic Pollu-
tants Laboratory, Centers for Disease Control and Preven-
tion (Atlanta, Georgia). The methodology used has been
published (25). Briefly, the serum samples were at first
automatically fortified with internal standards using Gilson
215 liquid handler (Gilson, Inc., Middleton, Wisconsin).
The samples were then extracted by automated liquid-liquid
extraction using a liquid handler. Removal of coextracted
lipids was performed on a silica:silica/sulfuric acid column
using the RapidTrace (Biotage; Uppsala, Sweden) equip-
ment for automation. The final analytical determinations
of PBDE and PBB congeners were performed by using
gas chromatography, isotope dilution, high-resolution mass
spectrometry employing a DFS (Thermo Fisher Scientific,
Waltham, Massachusetts) instrument.
Laboratory personnel were blinded to case and control
status. Internal laboratory controls included method blanks
(n = 3) and duplicates (n = 3) in every set of 24 study sam-
ples. Serum concentrations of PBDE and PBB congeners
were reported as the concentration after subtraction of the
median amount of the congener present as a contaminant in
blank samples.
A total of 11 PBDE congeners and 1 PBB congener
were measured (Table 1). The detection rates for each PBDE
and PBB congener were similar among cases and controls
(P values from the χ2 tests range: 0.089–0.90). Levels of
the 12 congeners were reported as lipid-corrected serum
concentration (ng/g of serum lipid). The distributions of
the concentrations were similar between cases and controls
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Table 1. Lipid-Corrected Serum Concentrations of Polybrominated Diphenyl Ether and Polybrominated Biphenyl Congeners (ng/g) Among
Cases of Papillary Thyroid Cancer and Controls in the Department of Defense Cohort, United States, 2000–2013
Congener
Median
LODa
Cases Controls
Detectedc
GM (GSD) Median (IQR)
Detectedc
GM (GSD) Median (IQR) P Valueb
No. % No. %
BDE-17 1.0 41 5.5 2.1 (2.0) –d 30 4.0 1.9 (1.9) –d 0.18
BDE-28 1.1 251 33.8 3.0 (2.5) <LOD (<LOD–1.5) 236 31.8 2.6 (2.3) <LOD (<LOD–1.3) 0.25
BDE-47 2.5 708 95.4 21.5 (3.7) 16.3 (7.9–38.8) 707 95.3 21.0 (3.2) 16.9 (8.4–38.6) 0.74
BDE-66 1.2 66 8.9 2.9 (2.3) –d 52 7.0 2.3 (2.1) –d 0.15
BDE-85 1.0 208 28.0 3.3 (3.0) <LOD (<LOD–1.0) 204 27.5 2.8 (2.6) <LOD (<LOD–1.0) 0.67
BDE-99 2.0 549 74.0 9.1 (3.6) 4.3 (<LOD–10.6) 577 77.8 8.2 (3.2) 4.4 (2.2–10.6) 0.60
BDE-100 1.0 621 83.7 5.7 (3.5) 3.4 (1.5–8.8) 643 86.7 5.4 (3.0) 3.7 (1.8–8.7) 0.43
BDE-153 1.0 679 91.5 6.4 (3.4) 4.3 (2.1–11.5) 691 93.1 6.3 (3.0) 4.6 (2.5–11.2) 0.37
BDE-154 1.0 217 29.3 3.0 (2.9) <LOD (<LOD–1.1) 209 28.2 2.6 (2.5) <LOD (<LOD–1.0) 0.56
BDE-183 1.1 79 10.7 1.7 (2.0) –d 85 11.5 1.5 (1.7) –d 0.68
BDE-209 5.2 62 8.4 9.7 (2.2) –d 80 10.8 8.5 (1.8) –d 0.14
BB-153 1.0 544 73.3 3.0 (2.3) 2.0 (<LOD–3.5) 550 74.1 3.1 (2.2) 2.1 (0.9–3.6) 0.36
Abbreviations: BB-153, 2,2′,4,4′,5,5′-hexabromobiphenyl; BDE-17, 2,2′,4-tribromodiphenyl ether; BDE-28, 2,4,4′-tribromodiphenyl ether;
BDE-47, 2,2′,4,4′-tetrabromodiphenyl ether; BDE-66, 2,3′,4′,4-tetrabromodiphenyl ether; BDE-85, 2,2′,3,4,4′-pentabromodiphenyl ether;
BDE-99, 2,2′,4,4′,5-pentabromodiphenyl ether; BDE-100, 2,2′,4,4′,6-pentabromodiphenyl ether; BDE-153, 2,2′,4,4′,5,5′-hexabromodiphenyl
ether; BDE-154, 2,2′,4,4′,5,6′-hexabromodiphenyl ether; BDE-183, 2,2′,3,4,4′,5′,6-heptabromodiphenyl ether; BDE-209, 2,2′,3,3′,4,4′,5,5′,6,6′-
decabromodiphenyl ether; GM, geometric mean; GSD, geometric standard deviation; IQR, interquartile range; LOD: limit of detection.
a Calculated among cases and controls combined.
b Estimated by the Mann-Whitney U test.
c Cases or controls whose serum samples containing PBDE or PBB congener had an amount above the limit of detection, and the value of
concentration is detectable.
d All values were below the limit of detection.
(P values from the Mann-Whitney U tests range: 0.14–
0.74). We also examined the distributions of concentrations
according to participants’ demographic characteristics and
military services; the results are summarized in Web Tables
1 and 2.
Statistical analyses
The distributions of demographic and military character-
istics were compared between cases and controls using the
χ2 test. Because the distributions of lipid-corrected serum
concentrations of PBDE and PBB congeners were right
skewed, they were compared between cases and controls
using the Mann-Whitney U test.
Among the 12 congeners measured, 7 PBDE congeners
(BDE-28, -47, -85, -99, -100, -153, and -154) and the PBB
congener (BB-153) that were detected in >20% of the
control samples were included in the final analyses. For the
5 congeners with≤25% of data below the limits of detection
(LODs) (BDE-47, -99, -100, and -153, and BB-153), the
lipid-corrected serum concentrations were categorized into
quartiles based on the distribution among controls, with
the first quartile used as the reference category. For con-
geners with >25% of data below the LODs (BDE-28, -85,
and -154), the reference values were defined as those below
the LODs, and the values above the LODs were categorized
into tertiles.
Given the individual-matched case-control design, con-
ditional logistic regression models were used to estimate
the associations between risk of PTC and levels of PBDE
and PBB congeners. We applied two approaches: single-
chemical models and multichemical models. Both single-
and multichemical models adjusted for body mass index
(BMI) and branch of military service. Additional adjustment
for the years between serum sample collection and PTC
diagnosis did not change the results, so this variable was not
included in the final models. In the single-chemical models,
the associations between risk of PTC and concentrations of
each PBDE congener and the PBB-153 were individually
estimated. In the multichemical model, we included all the
categorical PBDE and PBB congeners in one model to
additionally control for potential confounding from other
congeners. Given that the categorized congeners were not
highly correlated (Cramer’s V range: 0.05–0.73; Web Table
3), the estimated associations are not likely to be affected by
multicollinearity.
Statistical analyses were performed for histological sub-
type, classical PTC (ICD-O-3: 8050, 8260, 8341–8343), and
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Table 2. Distributions of Selected Characteristics Among Cases of Papillary Thyroid Cancer and Controls in the Department of Defense
Cohort, United States, 2000–2013
Characteristic
Cases Controls
P Valuea
No. % No. %
Age at serum sample collection, years
<20 124 16.7 121 16.3
20–29 348 46.9 352 47.4
30–40 220 29.7 221 29.8
≥40 50 6.7 48 6.5 0.99
Age at diagnosis, years
<30 210 28.3 203 27.4
30–39 310 41.8 323 43.5
40–49 185 24.9 179 24.1
≥50 37 5.0 37 5.0 0.92
Sex
Male 401 54.0 401 54.0
Female 341 46.0 341 46.0 1.00
Ethnicity
White 468 63.1 467 63.0
Black 131 17.7 132 17.8
Hispanic 68 9.2 68 9.2
Other 55 7.4 55 7.4
Unknown 20 2.7 20 2.7 1.00
BMIb
<25.0 257 34.6 285 38.4
25.0–29.9 148 20.0 129 17.4
≥30.0 16 2.2 10 1.4
Missing 321 43.3 318 42.9 0.25
Service
Army 300 40.4 263 35.4
Air Force 197 26.6 152 20.5
Marines and Coast Guard, combined 61 8.2 83 11.2
Navy 184 24.8 244 32.9 0.0002
Year of serum sample collection
1994–2000 570 76.8 571 77.0
2001–2004 135 18.2 133 17.9
2005–2009 37 5.0 38 5.1 0.99
Years between serum sample collection and
PTC diagnosis
<5 115 15.5
5–9 344 46.4
10–12 283 38.1
Histological subtype
Classical PTC 600 80.9
Follicular variant of PTC 142 19.1
Table continues
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Table 2. Continued
Characteristic
Cases Controls
P Valuea
No. % No. %
Tumor size, mm
≤10 235 31.7
>10 463 62.4
Missing 44 5.9
Abbreviations: BMI, body mass index; PTC, papillary thyroid cancer.
a Estimated by the χ2 test.
b Weight (kg)/height (m)2.
follicular variant of PTC (ICD-O-3: 8340), respectively. Fur-
ther stratified analyses were conducted according to tumor
size (classical PTC microcarcinoma with tumor size ≤10
mm and large classical PTC with tumor size >10 mm)
and then according to sex among classical PTC cases and
matched controls, but not for follicular variant of PTC due
to small case numbers. Dose-response relationships were
investigated using tests for trend by assigning each partic-
ipant the quartile number of PBDE and PBB congeners. A
sensitivity analysis was conducted by excluding participants
whose serum samples were drawn within a likely latency
period (<5 years before diagnosis) among classical PTC
cases and matched controls (26). The remaining participants
were stratified by tumor size and each cutpoint of years
between the time of serum sample collection and PTC diag-
nosis (5–12 years) to evaluate whether the timing of sample
collection modified the associations.
All tests were 2-sided with α = 0.05. Because 7 PBDE
and 1 PBB congeners were included in the final analysis,
a Bonferroni-adjusted α of 0.05/8 = 0.006 was applied
to control for multiple comparisons. Because single- and
multichemical models provided similar risk estimates, all
results are presented from the multichemical models. Statis-
tical analyses were conducted using SAS, version 9.4 (SAS
Institute, Inc.; Cary, North Carolina).
RESULTS
As shown in Table 2, PTC cases were more likely to have
served in the Army or Air Force at the time of diagnosis,
whereas controls were more likely to have served in the
Navy orMarines/Coast Guard. Because of matching criteria,
distributions of age, sex, race/ethnicity, and date of sample
drawn were similar between cases and controls. Distribu-
tion of BMI was also similar between cases and controls,
although there was a high percentage of participants with
missing BMI data.
All serum samples used for the measurement of PBDEs
and PBBs were drawn during 1994–2009 and 1,132–4,383
days (approximately 3–12 years) before the cases were
diagnosed with PTC. The median age at sample collection
was 25 years (interquartile range, 21–32 years).
An elevated risk of classical PTC was associated with
higher levels of BDE-28 (for the third tertile vs. below LOD,
odds ratio (OR) = 2.09, 95% confidence interval (CI): 1.05,
4.15; P for trend= 0.020) (Table 3), although the P for trend
was no longer significant after the Bonferroni adjustment.
A borderline significantly reduced odds ratio was observed
for the second tertile of BDE-85 (OR = 0.43, 95% CI:
0.19, 0.99). There were no associations between individual
PBDE congeners or PBB-153 and risk of follicular variant of
PTC.
When the analyses were further stratified by tumor size of
classical PTC, an increased risk associatedwith higher levels
of BDE-28 was observed only for large classical PTC (for
the second tertile vs. below LOD, OR= 2.35, 95% CI: 1.15,
4.80; for the third tertile vs. belowLOD,OR= 4.77, 95%CI:
1.84, 12.35; P for trend= 0.0014) (Table 4). The P for trend
remained significant after the Bonferroni adjustment. There
were significantly increased odds ratios for large classical
PTC with BDE-154 for the first and second tertiles versus
belowLOD (OR= 3.33, 95%CI: 1.50, 7.36, andOR= 3.40,
95% CI: 1.18, 9.85, respectively) but not for the third tertile
versus below LOD (P for trend = 0.039). For classical PTC
microcarcinoma, there were significantly decreased odds
ratios with BDE-154 for the second and third tertiles versus
belowLOD (OR= 0.15, 95%CI: 0.02, 0.93, andOR= 0.04,
95% CI: <0.01, 0.51, respectively; P for trend = 0.017). A
significantly reduced odds ratio was also observed for large
classical PTCwith the second tertile of BDE-85 (OR= 0.23,
95% CI: 0.08, 0.65). No association was observed for the
other PBDE and PBB congeners in relation to either large
classical PTC or classical PTC microcarcinoma.
Sex significantly modified the associations between levels
of BDE-28 and risk of large classical PTC (Table 5). The
association between serum levels of BDE-28 and risk of
large classical PTC was stronger in women (for the third
tertile vs. below LOD, OR = 10.74, 95% CI: 1.93, 59.72; P
for trend = 0.0054) than men (for the third tertile vs. below
LOD, OR = 3.39, 95% CI: 0.98, 11.71; P for trend = 0.071
and P for interaction = 0.0040). After Bonferroni adjust-
ment, the P for trend remained significant only among
women, and the effect modification by sex remained signif-
icant. No significant association was observed for the other
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Table 3. Risk of Papillary Thyroid Cancer Associated With Lipid-Corrected Serum Concentrations of Polybrominated Diphenyl Ether and
Polybrominated Biphenyl Congeners (ng/g) Among Cases and Controls, Stratified by Histological Subtype, Department of Defense Cohort,
United States, 2000–2013
Congener and
Concentration
Classical PTC Follicular Variant of PTC
No. of Casesa No. of Controlsa ORb 95% CI No. of Casesa No. of Controlsa ORb 95% CI
BDE-28
<LOD 383 406 1.00 Referent 97 88 1.00 Referent
>LOD–1.56 55 63 0.91 0.57, 1.45 16 15 1.06 0.40, 2.80
1.57–3.18 68 62 1.58 0.93, 2.69 11 17 0.42 0.12, 1.40
3.19–80.10 87 61 2.09 1.05, 4.15 14 18 0.39 0.07, 2.23
P for trendc 0.020 0.35
BDE-47
<LOD–8.43 159 150 1.00 Referent 36 32 1.00 Referent
8.44–16.91 141 150 1.16 0.74, 1.81 38 33 1.18 0.43, 3.26
16.92–38.63 137 142 1.37 0.74, 2.54 36 40 0.94 0.24, 3.58
38.64–2,189.00 156 150 1.00 0.41, 2.44 28 33 2.74 0.36, 20.64
P for trendc 0.89 0.95
BDE-85
<LOD 423 433 1.00 Referent 102 99 1.00 Referent
>LOD–1.68 61 55 1.06 0.58, 1.95 15 12 1.49 0.41, 5.44
1.69–3.18 30 56 0.43 0.19, 0.99 6 13 1.18 0.21, 6.52
3.19–79.08 81 53 1.76 0.57, 5.47 15 15 4.98 0.31, 79.67
P for trendc 0.64 0.34
BDE-99
<LOD–2.17 168 149 1.00 Referent 40 35 1.00 Referent
2.18–4.40 133 150 0.87 0.55, 1.35 29 34 0.93 0.37, 2.35
4.41–10.61 142 147 0.92 0.52, 1.62 39 37 1.88 0.53, 6.69
10.62–993.30 152 151 0.86 0.39, 1.87 30 33 1.65 0.32, 8.45
P for trendc 0.59 0.22
BDE-100
<LOD–1.84 177 151 1.00 Referent 39 31 1.00 Referent
1.85–3.71 134 148 0.73 0.46, 1.18 36 35 0.53 0.19, 1.47
3.72–8.65 120 144 0.61 0.32, 1.17 39 38 0.33 0.07, 1.53
8.66–368.00 162 149 0.67 0.27, 1.65 24 34 0.19 0.03, 1.41
P for trendc 0.29 0.13
BDE-153
<LOD–2.49 176 146 1.00 Referent 36 38 1.00 Referent
2.50–4.61 134 155 0.82 0.57, 1.18 38 29 1.91 0.84, 4.36
4.62–11.23 122 154 0.69 0.45, 1.08 39 30 2.08 0.81, 5.35
11.24–285.50 163 142 0.94 0.55, 1.61 25 42 0.78 0.24, 2.57
P for trendc 0.71 0.94
Table continues
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Table 3. Continued
Congener and
Concentration
Classical PTC Follicular Variant of PTC
No. of Casesa No. of Controlsa ORb 95% CI No. of Casesa No. of Controlsa ORb 95% CI
BDE-154
<LOD 412 426 1.00 Referent 102 95 1.00 Referent
>LOD–1.60 60 54 1.49 0.82, 2.70 16 15 0.97 0.29, 3.29
1.61–3.11 50 57 1.37 0.61, 3.07 6 13 0.39 0.07, 2.26
3.12–66.22 71 55 0.61 0.19, 1.99 14 15 0.85 0.06, 13.17
P for trendc 0.49 0.76
BB-153
<LOD–0.85 154 149 1.00 Referent 1.00 33 1.00 Referent
0.86–2.12 146 146 0.91 0.65, 1.28 38 37 0.87 0.41, 1.84
2.13–3.60 152 155 0.85 0.60, 1.21 31 27 1.25 0.56, 2.79
3.61–451.30 141 142 0.92 0.65, 1.31 32 41 0.76 0.35, 1.68
P for trendc 0.47 0.60
Abbreviations:BB-153, 2,2′,4,4′,5,5′-hexabromobiphenyl; BDE-28, 2,4,4′-tribromodiphenyl ether; BDE-47, 2,2′,4,4′-tetrabromodiphenyl ether;
BDE-85, 2,2′,3,4,4′-pentabromodiphenyl ether;BDE-99, 2,2′,4,4′,5-pentabromodiphenyl ether;BDE-100, 2,2′,4,4′,6-pentabromodiphenyl ether;
BDE-153, 2,2′,4,4′,5,5′-hexabromodiphenyl ether; BDE-154, 2,2′,4,4′,5,6′-hexabromodiphenyl ether; BMI, body mass index; CI, confidence
interval; LOD: limit of detection; OR, odds ratio; PBB, polybrominated biphenyl; PBDE, polybrominated diphenyl ether; PTC, papillary thyroid
cancer.
a Values in subgroups do not sum to the total due to nonreportable values.
b Multichemical conditional logistic regression, adjusted for all PBDE and PBB congeners, BMI (calculated as weight (kg)/height (m)2:<18.5,
18.5–24.9, 25.0–29.9, ≥30.0, or missing), and branch of military service (Army, Air Force, Navy, and Marines/Coast Guard).
c P values were not corrected for multiple comparison.
PBDE and PBB congeners among either men or women.
Null associations between levels of BDE-28 and risk of
classical PTC microcarcinoma were found among both men
and women (Web Table 4).
The association between BDE-28 and risk of classical
PTC was stronger after exclusion of case-control pairs
whose serum samples were drawn <5 years before cancer
diagnosis (for the second tertile vs. below LOD, OR= 1.80,
95% CI: 1.00, 3.21; for the third tertile vs. below LOD,
OR = 2.53, 95% CI: 1.19, 5.36; P for trend = 0.014) (Web
Table 5). The associations for most other congeners were
also slightly strengthened in this sensitivity analysis. Similar
associations were observed for BDE-153 before and after
exclusion samples drawn <5 years from diagnosis. There
was no effect modification by timing of sample collection for
either large classical PTC or classical PTC microcarcinoma
(data not shown).
DISCUSSION
In this large, nested case-control study among USmilitary
personnel, we found that increasing serum levels of BDE-28
were associated with an elevated risk of classical PTC. This
association was observed mainly for classical PTC among
cases with tumor size >10 mm, and it was stronger among
women.
The geometric means of concentration for BDE-28, -47,
-99, -100, and -153 and BB-153 in controls of this study
were higher than those in the US general population from
the NHANES 2003–2004 (14).Whenwe restricted our com-
parisons to the subset of our study population with serum
samples taken during 2003–2004, the geometric means were
comparable to those in theNHANES 2003–2004 population.
However, the 90th and 95th percentiles of concentrations
for most PBDE and PBB congeners in this study population
were lower than those in the NHANES 2003–2004 popula-
tion, indicating a more centralized range of concentrations
in the present military population than among the NHANES
general population. A similar range of concentrations was
observed only for BDE-153 between the study population
and NHANES 2003–2004 population.
Although accumulating evidence has illustrated that expo-
sure to PBDEs and PBBs alters thyroid hormone homeosta-
sis, the underlying mechanisms linking PBDEs and PBBs
to thyroid cancer are not fully understood. Because the
chemical structures of PBDE and PBB congeners are similar
to those of thyroid hormones, the hydroxylated metabolites
of PBDEs and PBBs could competitively bind to thyroid
hormone transport proteins and receptors (7). Addition-
ally, PBDEs can induce thyroid hormone metabolic enzyme
activity (7). These two potential mechanisms suggest that
PBDEs and PBBs could disrupt thyroid hormone home-
ostasis and could contribute to cancer risk and severity
(22).
In a recent prospective cohort study (27), investigators
reported that significant decrements in thyroid-stimulating
Am J Epidemiol. 2020;189(2):120–132
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Table 4. Risk of Classical Papillary Thyroid Cancer Associated With Lipid-Corrected Serum Concentrations of Polybrominated Diphenyl
Ether and Polybrominated Biphenyl Congeners (ng/g) Among Cases Controls, Stratified by Tumor Size, Department of Defense Cohort,
United States, 2000–2013
Congener and
Concentration
≤10 mm >10 mm
No. of Casesa No. of Controlsa ORb 95% CI No. of Casesa No. of Controlsa ORb 95% CI
BDE-28
<LOD 141 125 1.00 Referent 215 249 1.00 Referent
>LOD–1.56 14 22 0.47 0.19, 1.19 40 39 1.33 0.73, 2.42
1.57–3.18 22 22 0.82 0.30, 2.22 43 37 2.35 1.15, 4.80
3.19–80.10 25 30 0.55 0.16, 1.87 58 31 4.77 1.84, 12.35
P for trendc 0.57 0.0014
BDE-47
<LOD–8.43 62 48 1.00 Referent 89 91 1.00 Referent
8.44–16.91 44 47 0.99 0.43, 2.32 84 92 1.27 0.70, 2.30
16.92–38.63 44 50 1.23 0.41, 3.76 87 81 1.49 0.65, 3.46
38.64–2,189.00 52 54 2.86 0.48, 17.10 96 92 0.61 0.18, 2.10
P for trendc 0.54 0.75
BDE-85
<LOD 151 142 1.00 Referent 244 258 1.00 Referent
>LOD–1.68 19 22 2.68 0.81, 8.83 39 30 0.61 0.27, 1.38
1.69–3.18 7 14 3.93 0.52, 29.91 22 41 0.23 0.08, 0.65
3.19–79.08 25 24 13.41 0.97, 185.94 53 29 0.93 0.23, 3.83
P for trendc 0.017 0.067
BDE-99
<LOD–2.17 63 50 1.00 Referent 94 87 1.00 Referent
2.18–4.40 44 47 0.95 0.42, 2.15 82 92 0.83 0.46, 1.52
4.41–10.61 46 49 1.16 0.42, 3.19 86 88 0.74 0.34, 1.62
10.62–993.30 49 56 0.90 0.19, 4.34 96 91 0.68 0.24, 1.92
P for trendc 0.92 0.46
BDE-100
<LOD–1.84 69 49 1.00 Referent 97 86 1.00 Referent
1.85–3.71 43 48 0.57 0.25, 1.33 82 95 0.66 0.35, 1.25
3.72–8.65 43 49 0.51 0.16, 1.65 70 82 0.61 0.25, 1.48
8.66–368.00 47 53 0.26 0.05, 1.32 107 93 0.83 0.24, 2.82
P for trendc 0.094 0.72
BDE-153
<LOD–2.49 67 49 1.00 Referent 98 86 1.00 Referent
2.50–4.61 48 57 0.76 0.40, 1.44 76 86 0.94 0.58, 1.53
4.62–11.23 38 55 0.80 0.37, 1.76 81 87 0.84 0.47, 1.50
11.24–285.50 49 41 2.74 0.96, 7.86 103 99 0.66 0.33, 1.32
P for trendc 0.21 0.33
BDE-154
<LOD 155 135 1.00 Referent 230 258 1.00 Referent
>LOD–1.60 14 20 0.35 0.11, 1.14 44 31 3.33 1.50, 7.36
1.61–3.11 10 18 0.15 0.02, 0.93 37 38 3.40 1.18, 9.85
3.12–66.22 23 26 0.04 <0.01, 0.51 45 29 1.74 0.39, 7.80
P for trendc 0.017 0.039
Table continues
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Table 4. Continued
Congener and
Concentration
≤10 mm >10 mm
No. of Casesa No. of Controlsa ORb 95% CI No. of Casesa No. of Controlsa ORb 95% CI
BB-153
<LOD–0.85 48 43 1.00 Referent 92 92 1.00 Referent
0.86–2.12 51 49 1.02 0.55, 1.90 88 84 0.81 0.51, 1.28
2.13–3.60 55 54 0.86 0.46, 1.62 90 95 0.74 0.47, 1.18
3.61–451.30 48 53 0.87 0.45, 1.67 86 85 0.85 0.54, 1.36
P for trendc 0.42 0.67
Abbreviation: BB-153, 2,2′,4,4′,5,5′-hexabromobiphenyl; BDE-28, 2,4,4′-tribromodiphenyl ether; BDE-47, 2,2′,4,4′-tetrabromodiphenyl
ether; BDE-85, 2,2′,3,4,4′-pentabromodiphenyl ether; BDE-99, 2,2′,4,4′,5-pentabromodiphenyl ether; BDE-100, 2,2′,4,4′,6-pentab-
romodiphenyl ether; BDE-153, 2,2′,4,4′,5,5′-hexabromodiphenyl ether; BDE-154, 2,2′,4,4′,5,6′-hexabromodiphenyl ether; BMI, body mass
index; CI, confidence interval; LOD: limit of detection; OR, odds ratio; PBB, polybrominated biphenyl; PBDE, polybrominated diphenyl ether;
PTC, papillary thyroid cancer.
a Values in subgroups do not sum to the total due to nonreportable values.
b Multichemical conditional logistic regression, adjusted for all PBDE and PBB congeners, BMI (calculated as weight (kg)/height (m)2:
<18.5, 18.5–24.9, 25.0–29.9, ≥30.0, or missing), and branch of military service (Army, Air Force, Navy, and Marines/Coast Guard).
c P values were not corrected for multiple comparison.
hormone levels of 3-year-olds were associated with
increased prenatal serum concentrations of several PBDE
congeners, including BDE-28. This inverse relationship was
modified by child sex, with stronger decrease in thyroid-
stimulating hormone among girls. Because there is an
indication from two other prospective cohort studies (24,
28) that lower levels of thyroid-stimulating hormone are
associated with a significantly increased risk of thyroid
cancer, it is possible that elevated levels of BDE-28 increase
the risk of classical PTC through the mediation of thyroid-
stimulating hormone.
Although the latency period between chemical expo-
sure and appearance of thyroid cancer is still unclear,
a latency period of 5–10 years has been reported for
thyroid cancer after radiation exposure (26). The present
study included only samples collected ≥3 years before
PTC diagnosis. We also observed a stronger association
between BDE-28 and risk of classical PTC among cases
whose serum samples were drawn ≥5 years before cancer
diagnosis.
To our knowledge, only two epidemiologic studies have
investigated the associations between PBDE congeners and
risk of thyroid cancer. One hospital-based case-control study
investigated PBDEs in house dust and serum samples of 70
PTC cases and 70 noncancer controls (22). An elevated risk
of PTC associated with a higher dust level of BDE-209 was
observed, but no association with serum concentrations of
any PBDE congeners was reported. Another nested case-
control study including 104 incident thyroid cancer cases
and 207 matched controls in the Prostate, Lung, Colorectal,
and Ovarian Cancer Screening Trial cohort reported no
association between PBDEs and risk of thyroid cancer. The
main congener found to be associated with PTC risk in our
study (i.e., BDE-28) had a low detection rate in both previous
studies, and the risk of thyroid cancer was not evaluated.
BDE-28 mainly exists in the penta-BDE commercial
mixture (11), which is commonly used as flame retardant
in flexible polyurethane foam and is also used in printed
circuit boards and other applications. A recent study reported
a unique trend of BDE-28 body burdens, which was decreas-
ing from 2008–2009 to 2011–2012, flattened between
2011–2012 and 2014, and then increasing in 2014, among
pregnant women in California (11). This recently increasing
trend of BDE-28 might be due to the debromination of the
higher brominated congeners (11), but this possibility must
still be further explored.
The present study has several strengths. The sample size
was relatively large, providing sufficient statistical power
to investigate and compare the associations by sex, which
is important because women are approximately 3 times
more likely to develop thyroid cancer than men. The study
population was composed entirely of US active-duty mil-
itary personnel, a younger population that represents the
age groups at which thyroid cancer risk is at its highest.
Additionally, the single-payer, universal (i.e., equal access)
military health-care system minimizes potential selection
bias from differences in access to medical care. Although
we did not suspect a specific source of exposure to PBDEs
related to military service, PBDEs are persistent, with half-
life ranges of 3–12 years, and temporal trends of levels
measured in the environment suggest that human exposure
is widespread despite bans on the various BDEs. The levels
of PBDE and PBB congeners were prospectively assessed
in the Department of Defense Serum Repository cohort,
which provides an opportunity to estimate potentially causal
relationships between exposure to these chemicals and risk
of thyroid cancer.
The limitations of this study should also be considered.
There was a lack of information on several potential
confounding factors, such as ionizing radiation exposure,
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Table 5. Risk of Large Classical Papillary Thyroid Cancer (>10mm) AssociatedWith Lipid-Corrected SerumConcentrations of Polybrominated
Diphenyl Ether and Polybrominated Biphenyl Congeners (ng/g) Among Cases and Controls, Stratified by Sex, Department of Defense Cohort,
United States, 2000–2013
Congener and
Concentration
Male Female
P for
InteractionbNo. of
Casesa
No. of
Controlsa
ORb 95% CI
No. of
Casesa
No. of
Controlsa
ORb 95% CI
BDE-28
<LOD 129 138 1.00 Referent 86 111 1.00 Referent
>LOD–1.56 25 21 1.50 0.69, 3.26 15 18 1.13 0.39, 3.30
1.57–3.18 26 25 2.07 0.86, 4.94 17 12 3.56 0.87, 14.63
3.19–80.10 26 20 3.39 0.98, 11.71 32 11 10.74 1.93, 59.72
P for trendc 0.071 0.0054 0.0040
BDE-47
<LOD–8.43 52 50 1.00 Referent 37 41 1.00 Referent
8.44–16.91 52 46 1.26 0.56, 2.82 32 46 1.43 0.57, 3.59
16.92–38.63 56 54 0.94 0.31, 2.87 31 27 3.08 0.79, 12.02
38.64–2,189.00 46 54 0.41 0.08, 2.12 50 38 0.67 0.07, 6.09
P for trendc 0.47 0.70 0.0095
BDE-85
<LOD 148 142 1.00 Referent 96 116 1.00 Referent
>LOD–1.68 25 23 0.56 0.21, 1.45 14 7 1.03 0.17, 6.40
1.69–3.18 11 21 0.28 0.08, 1.02 11 20 0.17 0.02, 1.49
3.19–79.08 22 19 0.40 0.07, 2.52 31 10 2.46 0.12, 51.74
P for trendc 0.065 0.50 0.0087
BDE-99
<LOD–2.17 54 47 1.00 Referent 40 40 1.00 Referent
2.18–4.40 51 50 0.89 0.39, 2.03 31 42 0.72 0.29, 1.81
4.41–10.61 52 52 1.02 0.34, 3.02 34 36 0.48 0.14, 1.61
10.62–993.30 49 56 1.00 0.24, 4.25 47 35 0.51 0.09, 2.85
P for trendc 0.92 0.33 0.036
BDE-100
<LOD–1.84 55 45 1.00 Referent 42 41 1.00 Referent
1.85–3.71 49 48 0.74 0.31, 1.77 33 47 0.58 0.21, 1.56
3.72–8.65 46 52 0.73 0.22, 2.35 24 30 0.43 0.10, 1.89
8.66–368.00 56 59 0.89 0.18, 4.36 51 34 0.91 0.09, 9.18
P for trendc 0.88 0.60 0.014
BDE-153
<LOD–2.49 48 32 1.00 Referent 50 54 1.00 Referent
2.50–4.61 45 49 0.78 0.40, 1.54 31 37 0.95 0.44, 2.07
4.62–11.23 51 55 0.82 0.38, 1.76 30 32 0.70 0.25, 1.96
11.24–285.50 62 69 0.59 0.23, 1.55 41 30 0.59 0.18, 1.91
P for trendc 0.39 0.50 0.077
Table continues
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Table 5. Continued
Congener and
Concentration
Male Female
P for
InteractionbNo. of
Casesa
No. of
Controlsa
ORb 95% CI
No. of
Casesa
No. of
Controlsa
ORb 95% CI
BDE-154
<LOD 139 141 1.00 Referent 91 117 1.00 Referent
>LOD–1.60 28 22 2.57 0.98, 6.73 16 9 4.43 0.94, 20.80
1.61–3.11 18 24 2.59 0.69, 9.64 19 14 4.65 0.56, 38.40
3.12–66.22 21 17 3.45 0.52, 22.96 24 12 0.54 0.02, 13.54
P for trendc 0.061 0.40 0.0070
BB-153
<LOD–0.85 41 34 1.00 Referent 51 58 1.00 Referent
0.86–2.12 41 41 0.66 0.32, 1.35 47 43 0.84 0.44, 1.63
2.13–3.60 61 63 0.67 0.35, 1.27 29 32 0.83 0.40, 1.75
3.61–451.30 63 66 0.70 0.37, 1.34 23 19 0.99 0.42, 2.32
P for trendc 0.46 0.92 0.16
Abbreviations:BB-153, 2,2′,4,4′,5,5′-hexabromobiphenyl; BDE-28, 2,4,4′-tribromodiphenyl ether; BDE-47, 2,2′,4,4′-tetrabromodiphenyl ether;
BDE-85, 2,2′,3,4,4′-pentabromodiphenyl ether;BDE-99, 2,2′,4,4′,5-pentabromodiphenyl ether;BDE-100, 2,2′,4,4′,6-pentabromodiphenyl ether;
BDE-153, 2,2′,4,4′,5,5′-hexabromodiphenyl ether; BDE-154, 2,2′,4,4′,5,6′-hexabromodiphenyl ether; BMI, body mass index; CI, confidence
interval; LOD: limit of detection; OR, odds ratio; PBB, polybrominated biphenyl; PBDE, polybrominated diphenyl ether.
a Values in subgroups do not sum to the total due to nonreportable values.
b Multichemical conditional logistic regression, adjusted for all PBDE and PBB congeners, BMI (calculated as weight (kg)/height (m)2:<18.5,
18.5–24.9, 25.0–29.9, ≥30.0, or missing), and branch of military service (Army, Air Force, Navy, and Marines/Coast Guard).
c P values were not corrected for multiple comparison.
history of benign thyroid disease, and a family history of
thyroid cancer. Also, a high percentage of participants were
missing BMI data, which could have led to insufficient
adjustment for BMI. Previous evidence has suggested lower
prevalence of obesity and larger lean body mass among
military personnel than the US civilian population (29),
indicating less variation of BMI among the US military
personnel. Thus, any residual confounding of BMI would
likely be minimized in this study population. We also
restricted the analysis among case-control pairs who had
BMI measurements; the associations remained the same.
Furthermore, the stratified analyses and the results for
follicular variant of PTC could have yielded unstable results
due to the small subgroup counts. It is also possible that
the findings for BDE-28 were observed by chance due to
multiple comparisons. However, the association between
BDE-28 and large classical PTC remained statistically
significant after Bonferroni adjustment, indicating a true
association.
In conclusion, this large nested case-control study sug-
gested a significantly increased risk of classical PTC asso-
ciated with increasing levels of BDE-28. This increased
risk was found for cases with a tumor size >10 mm, and
particularly among women. Because a recent study reported
an increasing trend of BDE-28 concentrations in the serum
of pregnant women in California in 2008–2014 (11), and
accumulated evidence has suggested potential adverse influ-
ence on the thyroid for PBDE alternatives (22, 30), further
investigation into the association between BDE-28, other
PBDE congeners and alternatives, and thyroid cancer is
warranted. Additionally, more epidemiologic studies among
different populations are also warranted to confirm these
findings and identify high-risk populations who are suscep-
tible to these chemicals.
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